WASHINGTON — HHS confirmed Wednesday that FDA advisory panelists must demonstrate a direct financial interest in the substances they evaluate. Officials stated this ensures regulators possess 'skin in the game' regarding health outcomes. "It eliminates the bias of impartiality," said HHS Communications Director Alan Merrick. "You cannot understand a peptide's value unless your mortgage depends on its approval."